2m 2m 2m 2m 2m 2m 2m
PMV PHARMA (PMVP)
NASDAQ
$1.16$0.00 (0.00%)
Price as of Jun 03, 2026 6:59 PM EDT- $64.0MMarket Cap
- 28.36%1-Year Change
- BiotechnologyIndustry
PMV PHARMA (PMVP)
$1.16$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 6.3M -40.53% | 10.7M -4.62% | 11.2M +208.00% | 3.6M +707.80% | |
Cost of Revenue | 200,000 +6.95% | 187,000 +103.26% | 92,000 N/A | N/A N/A | |
Gross Profit | 6.1M -41.37% | 10.5M -5.51% | 11.1M +205.46% | 3.6M +707.80% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -69.9M +19.39% | -58.5M +4.73% | -55.9M +7.50% | -52.0M +42.46% | |
Depreciation and Amortization Expense | 133,000 -88.37% | 1.1M -8.99% | 1.3M +299.05% | 315,000 +2.61% | |
Total Operating Expenses | 86.2M +0.89% | 85.4M +6.63% | 80.1M +4.01% | 77.0M +32.16% | |
Operating Profit | -86.2M +0.89% | -85.4M +6.63% | -80.1M +4.01% | -77.0M +32.16% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 6.3M -40.86% | 10.6M -4.79% | 11.2M +200.86% | 3.7M +690.21% | |
Income before Taxes | -79.9M +6.82% | -74.8M +8.48% | -69.0M -5.96% | -73.3M +26.81% | |
Income Taxes | -2.2M -86.51% | -16.1M -805,100.00% | 2,000 +122.22% | -9,000 -139.13% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -77.7M +32.42% | -58.7M -14.87% | -69.0M -5.94% | -73.3M +26.75% | |
Net Income from Continuing Operations Applicable to Common | -79.9M +6.82% | -74.8M +8.48% | -69.0M -5.96% | -73.3M +26.81% | |
Basic EPS and Net Income | -1.48 +29.82% | -1.14 -20.83% | -1.44 -10.56% | -1.61 +25.78% | |
Diluted EPS and Net Income | -1.48 +29.82% | -1.14 -20.83% | -1.44 -10.56% | -1.61 +25.78% | |
Basic Weighted Average Shares | 52.5M +1.87% | 51.6M +7.42% | 48.0M +5.31% | 45.6M +1.01% | |
Diluted Weighted Average Shares | 52.5M +1.87% | 51.6M +7.42% | 48.0M +5.31% | 45.6M +1.01% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 38.0M -7.08% | 40.9M +8.41% | 37.7M -65.18% | 108.3M -37.21% | |
Short-Term Investments | 75.0M -41.70% | 128.6M -22.24% | 165.4M +24.55% | 132.8M +6.46% | |
Cash and Cash Equivalents and Short-Term Investments | 112.9M -33.35% | 169.5M -16.55% | 203.1M -15.76% | 241.1M -18.88% | |
Total Current Assets | 115.2M -34.40% | 175.7M -15.31% | 207.4M -16.03% | 247.0M -18.02% | |
Accumulated Depreciation | 1.3M -9.11% | 1.5M -55.35% | 3.3M +49.73% | 2.2M +16.92% | |
Property and Plant and Equipment and Net | 237,000 -42.05% | 409,000 -96.17% | 10.7M -2.64% | 11.0M +254.53% | |
Total Long-Term Assets | 297,000 +26.38% | 235,000 +23.68% | 190,000 -39.30% | 313,000 +41.63% | |
Total Assets | 116.6M -39.06% | 191.3M -24.14% | 252.2M -6.72% | 270.3M -18.48% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 622,000 0.00% | 622,000 N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 11.4M -20.56% | 14.4M +2.43% | 14.0M +29.51% | 10.8M -11.35% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 435,000 -48.09% | 838,000 -93.26% | 12.4M -7.54% | 13.4M +24.63% | |
Total Liabilities | 11.8M -22.08% | 15.2M -42.53% | 26.5M +8.99% | 24.3M +5.52% | |
Retained Earnings | -446.5M +21.08% | -368.7M +18.94% | -310.0M +28.61% | -241.0M +43.71% | |
Total Stockholders Equity | 104.7M -40.53% | 176.1M -21.98% | 225.7M -8.27% | 246.0M -20.27% | |
Total Shares Outstanding | 53.3M +2.69% | 51.9M +0.95% | 51.4M +12.40% | 45.8M +0.74% | |
Cash Flow | |||||
Cash from Operating Activities | -73.6M +43.48% | -51.3M -7.86% | -55.7M -12.71% | -63.8M +36.91% | |
Capital Expenditures | 29,000 -95.57% | 655,000 -31.91% | 962,000 -87.95% | 8.0M +491.85% | |
Cash from Investing Activities | 70.2M +31.53% | 53.4M +205.55% | -50.5M +3,594.81% | -1.4M -99.05% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 505,000 +61.34% | 313,000 -99.12% | 35.6M +3,613.67% | 958,000 -52.62% | |
Financials Ratio | |||||
Gross Margin | 96.84% -1.43% | 98.25% -0.94% | 99.18% N/A | N/A N/A | |
Operating Margin | -1,360.36% +69.63% | -801.95% +11.80% | -717.32% -66.23% | -2,124.07% -83.64% | |
Return on Assets | -50.51% +90.74% | -26.48% +0.31% | -26.40% +8.35% | -24.36% +46.80% | |
Return on Equity | -55.37% +89.47% | -29.23% -0.04% | -29.24% +10.58% | -26.44% +52.59% | |
Revenue Growth | -40.53% +777.35% | -4.62% -102.22% | 208.00% -70.61% | 707.80% +2,381.06% | |
Current Ratio | 10.09 -17.42% | 12.22 -17.32% | 14.78 -35.17% | 22.80 -7.52% | |
Cash Ratio | 3.33 +16.98% | 2.84 +5.83% | 2.69 -73.12% | 10.00 -29.17% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow